Effectiveness of CAR-T treatment toward the potential risk of second malignancies
- PMID: 38756776
- PMCID: PMC11096564
- DOI: 10.3389/fimmu.2024.1384002
Effectiveness of CAR-T treatment toward the potential risk of second malignancies
Keywords: car-t; follow-up; malignancies; second cancer; therapy.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy.Blood Cancer Discov. 2024 Jul 1;5(4):249-257. doi: 10.1158/2643-3230.BCD-23-0272. Blood Cancer Discov. 2024. PMID: 38713831 Review.
-
Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.Transplant Cell Ther. 2024 Oct;30(10):936-938. doi: 10.1016/j.jtct.2024.09.002. Transplant Cell Ther. 2024. PMID: 39326982 No abstract available.
-
Chimeric Antigen Receptor (CAR) T-Cell Therapy.JAMA Oncol. 2017 Nov 1;3(11):1595. doi: 10.1001/jamaoncol.2017.2989. JAMA Oncol. 2017. PMID: 28880983 No abstract available.
-
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.Clin Cancer Res. 2024 Oct 15;30(20):4690-4700. doi: 10.1158/1078-0432.CCR-24-1798. Clin Cancer Res. 2024. PMID: 39256908
-
CAR T Cell Therapy for Hematological Malignancies.Curr Med Sci. 2019 Dec;39(6):874-882. doi: 10.1007/s11596-019-2118-z. Epub 2019 Dec 16. Curr Med Sci. 2019. PMID: 31845217 Review.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources